Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

被引：5
|
作者：
Prat, Aleix
Modi, Shanu
Tsurutani, Junji
Cameron, David
Harbeck, Nadia
Garrido, Charo
Karnoub, Maha
Hsu, Ching
Feng, Wenquin
Yung, Lotus
Wang, Yibin
Gambhire, Dhiraj
Ford, Shirin K.
Vitazka, Patrik
Ueno, Naoto T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-HER2-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2-18
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Determination of HER2-Low Status in Tumors of Patients With Unresectable and/or Metastatic Breast Cancer in DESTINY-Breast04
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 8 - 9
  • [2] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [3] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
    Tsurutani, Junji
    Modi, Shanu
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Wang, Xiaojia
    Li, Wei
    Im, Seock-Ah
    Xu, Binghe
    Lu, Yen-Shen
    Gambhire, Dhiraj
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379
  • [4] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
    Zhan, Mei
    Huang, Zijia
    Xu, Ting
    Xu, Xinyi
    Zheng, Hanrui
    Wu, Fengbo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [5] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [6] Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer
    Fessler, Beate
    BREAST CARE, 2023, 18 (02)
  • [7] Provider perceptions of DESTINY-Breast04, HER2-low directed treatment, and interstitial lung disease
    Leon, Brooke
    Bone, Robert
    Jeune-Smith, Yolaine
    Feinberg, Bruce
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
  • [9] Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Ueno, N. T.
    Niikura, N.
    Yamashita, T.
    Jacot, W.
    Cameron, D. A.
    Tsurutani, J.
    Sohn, J.
    Tokunaga, E.
    Vidal Losada, M. J.
    Park, Y. H.
    Lee, K. S.
    Chae, Y. S.
    Prat, A.
    Suto, F.
    Kuwahara, Y.
    Boran, A. D.
    Kobayashi, M.
    Kumar, V.
    Aguilar, C. Orbegoso
    Modi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S401 - S402
  • [10] DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
    Wang, Fei
    Yuan, Peng
    TRANSLATIONAL BREAST CANCER RESEARCH, 2025, 6
12345